These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22876522)

  • 1. Hemoglobin A1c outcomes and health care resource use in type 2 diabetes mellitus patients treated with combination oral antidiabetic drugs through step therapy and loose-dose and fixed-dose combinations.
    Williams SA; Buysman EK; Hulbert EM; Bergeson JG; Zhang B; Graham J
    Manag Care; 2012 Jul; 21(7):40-8. PubMed ID: 22876522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs. loose-dose combination of oral anti-diabetes drugs.
    Lokhandwala T; Smith N; Sternhufvud C; Sörstadius E; Lee WC; Mukherjee J
    J Med Econ; 2016; 19(3):203-12. PubMed ID: 26473990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin.
    Engel SS; Seck TL; Golm GT; Meehan AG; Kaufman KD; Goldstein BJ
    Endocr Pract; 2013; 19(5):751-7. PubMed ID: 23757615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Economic Outcomes of Patients with Type 2 Diabetes on Multiple Daily Injections of Basal-bolus Insulin (MDI) Therapy: A Retrospective Cohort Study.
    Brixner D; Ermakova A; Xiong Y; Sieradzan R; Sacks N; Cyr P; Taylor SD
    Clin Ther; 2019 Feb; 41(2):303-313.e1. PubMed ID: 30709610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and economic outcomes among patients with diabetes mellitus initiating insulin glargine pen versus vial.
    Grabner M; Chu J; Raparla S; Quimbo R; Zhou S; Conoshenti J
    Postgrad Med; 2013 May; 125(3):204-13. PubMed ID: 23748521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet.
    Raskin P; Lewin A; Reinhardt R; Lyness W;
    Diabetes Obes Metab; 2009 Sep; 11(9):865-73. PubMed ID: 19476470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.
    Olansky L; Reasner C; Seck TL; Williams-Herman DE; Chen M; Terranella L; Mehta A; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2011 Sep; 13(9):841-9. PubMed ID: 21535346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.
    Reasner C; Olansky L; Seck TL; Williams-Herman DE; Chen M; Terranella L; Johnson-Levonas AO; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2011 Jul; 13(7):644-52. PubMed ID: 21410627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance.
    Benford M; Milligan G; Pike J; Anderson P; Piercy J; Fermer S
    Adv Ther; 2012 Jan; 29(1):26-40. PubMed ID: 22246944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycemic Improvement with a Fixed-dose combination of DPP-4 inhibitor + metformin in patients with Type 2 diabetes (GIFT study).
    Bajaj HS; Ye C; Jain E; Venn K; Stein E; Aronson R
    Diabetes Obes Metab; 2018 Jan; 20(1):195-199. PubMed ID: 28640433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
    Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
    Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality measure attainment in patients with type 2 diabetes mellitus.
    Lafeuille MH; Grittner AM; Gravel J; Bailey RA; Martin S; Garber L; Sheng Duh M; Lefebvre P
    Am J Manag Care; 2014 Jan; 20(1 Suppl):s5-15. PubMed ID: 24512194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control.
    Raskin P; Lewin A; Reinhardt R; Lyness W;
    Diabetes Obes Metab; 2009 Oct; 11(10):947-52. PubMed ID: 19531054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.
    Lage MJ; Fabunmi R; Boye KS; Misurski DA
    Adv Ther; 2009 Feb; 26(2):217-29. PubMed ID: 19219409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acarbose plus metformin fixed-dose combination outperforms acarbose monotherapy for type 2 diabetes.
    Wang JS; Huang CN; Hung YJ; Kwok CF; Sun JH; Pei D; Yang CY; Chen CC; Lin CL; Sheu WH;
    Diabetes Res Clin Pract; 2013 Oct; 102(1):16-24. PubMed ID: 23993469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare utilization changes in relation to treatment intensification with insulin aspart in patients with type 2 diabetes. Data from a large US managed-care organization.
    Aagren M; Luo W; Moës E
    J Med Econ; 2010 Mar; 13(1):16-22. PubMed ID: 19958212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the relationship between diabetes treatment intensification and quality measure performance using electronic medical records.
    Arnold RJG; Yang S; Gold EJ; Farahbakhshian S; Sheehan JJ
    PLoS One; 2018; 13(6):e0199011. PubMed ID: 29894495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
    J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations.
    Ferrario CM; Panjabi S; Buzinec P; Swindle JP
    Ther Adv Cardiovasc Dis; 2013 Feb; 7(1):27-39. PubMed ID: 23328188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
    Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
    J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.